---
schema_version: "secwatch.filing_event.v1"
accession: "0001790340-25-000039"
form_type: "8-K"
ticker: "IMRX"
cik: "0001790340"
company_name: "Immuneering Corp"
filed_at: "2025-03-20T23:59:59+00:00"
generated_at: "2026-05-24T10:30:55.930998+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Immuneering reports positive Phase 2a data for IMM-1-104 in pancreatic cancer; cash runway into 2026

## Summary
- Phase 2a data: IMM-1-104 + mGnP showed 43% ORR, 86% DCR; + mFFX showed 50% ORR vs historic 23% and 32%.
- Planning underway for potential global pivotal trial of IMM-1-104 in first-line pancreatic cancer.
- Cash $36.1M at Dec 31, 2024; plus $13.7M from ATM in Jan 2025; runway into 2026.
- Named Dr. Igor Matushansky as Chief Medical Officer to lead clinical programs.
- Phase 1 pancreatic cancer patient on IMM-1-104 monotherapy for 13+ months with stable disease and 91% CA 19-9 reduction.

## SEC filing metadata
- accession: 0001790340-25-000039
- form_type: 8-K
- ticker: IMRX
- cik: 0001790340
- company_name: Immuneering Corp
- filed_at: 2025-03-20T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1790340/000179034025000039/0001790340-25-000039-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1790340/000179034025000039/imrx-20250320.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001790340-25-000039
- JSON: https://secwatch.observer/filing/0001790340-25-000039.json
- Plain text: https://secwatch.observer/filing/0001790340-25-000039.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.